Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability

These studies, with the longest (maximum: 3.3 years) duration of any reported Ig replacement trials in children with primary immunodeficiency diseases, showed low infection, local and systemic reaction rates along with well-tolerated infusions given in a single site.